Shares of Merck & Co. Inc. MRK slipped 1.43% to $113.09 Thursday, on what proved to be an all-around favorable trading ...

Merck (MRK) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, ...

We recently compiled a list of the 7 Undervalued Blue Chip Stocks To Buy Right Now. In this article, we are going to take a ...

Shares of Merck (MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven trading sessions, where shares fell overall 5.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Merck & Co.’s stock fell 0.5% premarket Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal ...

When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical ...

Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates.

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The ...